Sponsor Check › Issuer
Corporation · organized in DELAWARE · formed more than five years before filing · BALA CYNWYD, PA · SEC CIK 1374690 · formerly ZAFGEN, INC.; ZAFGEN INC
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Jun 10, 2020 · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known only from an approved profile claim or its Form ADV) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.
1 of 6 offerings reports sales commissions totalling $4,800,000; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jun 10, 2020 D File 021-368640 | $4,800,000 (est.) | $0 | $0 | MTS Partners no CRD number reported |
| EDGAR ↗ | Jun 10, 2020 D File 021-368642 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 5, 2012 D File 021-187910 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 28, 2012 D File 021-183316 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 12, 2011 D File 021-162666 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Mar 2, 2010 D/A File 021-94401 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
0 recorded documents and 0 ownership records matched to Larimar Therapeutics, Inc. in the sources searched.
Not found in sources searched (no on-demand check has run yet): NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c); NYC PLUTO ownership via NYC Open Data (64uk-42ks); Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp); Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files). Records in other counties, and recorder indexes we do not yet cover, were not searched.
Property records coverage: New York City (ACRIS recorded documents and ownership, refreshed monthly); Hillsborough County FL (recorded documents from Oct 14, 2026 forward; ownership from FL DOR roll 2026); Cook County IL, Harris County TX, Dallas County TX (assessor ownership and deed/sale records only); Miami-Dade County FL (ownership from FL DOR roll only; Clerk recorded documents not yet searched). Recorder indexes for TX, AZ, IL and WA counties, mortgages and liens outside NYC and FL, lis pendens and foreclosure notices everywhere, Miami-Dade County FL recorded documents, Maricopa County AZ, King County WA, Salt Lake County UT, and all other counties are not yet searched. Last refresh: Oct 23, 2026, 11:02 PM ET. Sources searched: Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files), 2 daily files (Oct 14, 2026 to Oct 15, 2026) — loaded Oct 23, 2026, 8:59 PM ET · Florida DOR NAL roll (Hillsborough 39) roll year 2026 — loaded Oct 23, 2026, 8:54 PM ET · Florida DOR NAL roll (Dade 23) roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET · Harris County Appraisal District real_acct.txt roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET · Dallas Central Appraisal District ACCOUNT_INFO.CSV roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET. Not yet searched for this issuer (queued): NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) · NYC PLUTO ownership via NYC Open Data (64uk-42ks) · Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp). Counterparties that are not business entities are shown as "an individual (name withheld)"; residential addresses are never shown. Items still in human review are not shown.
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|---|---|---|---|---|---|
| 021-368642 | Jun 10, 2020 EDGAR ↗ | Jun 10, 2020 D EDGAR ↗ | 0 | $82,079,593 | $82,079,593 | Biotechnology |
| 021-368640 | Jun 10, 2020 EDGAR ↗ | Jun 10, 2020 D EDGAR ↗ | 0 | $80,000,000 | $80,000,000 | Biotechnology |
| 021-187910 | Dec 5, 2012 EDGAR ↗ | Dec 5, 2012 D EDGAR ↗ | 0 | Indefinite | $21,761,570 | Other Health Care |
| 021-183316 | Aug 28, 2012 EDGAR ↗ | Aug 28, 2012 D EDGAR ↗ | 0 | Indefinite | $3,000,000 | Other Health Care |
| 021-162666 | Jul 12, 2011 EDGAR ↗ | Jul 12, 2011 D EDGAR ↗ | 0 | Indefinite | $6,085,933 | Other Health Care |
| 021-94401 | Mar 1, 2010 EDGAR ↗ | Mar 2, 2010 D/A EDGAR ↗ | 1 latest Mar 2, 2010 | $10,125,000 | $8,100,000 | Other Health Care |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
| Filing | Form D filed Jun 10, 2020 SEC file no. 021-368642 · accession 0001192482-20-000457 |
|---|---|
| Raise progress | $82,079,593 sold of $82,079,593 offered (100%) · $0 remaining · first sale May 28, 2020 |
| Filing timing | Date of first sale: May 28, 2020 · Form D filed: Jun 10, 2020 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,340 days (6.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity · business combination transaction |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Michael Celano, Chief Financial Officer (Jun 6, 2020) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $82,079,593. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Jun 10, 2020 SEC file no. 021-368640 · accession 0001192482-20-000456 |
|---|---|
| Raise progress | $80,000,000 sold of $80,000,000 offered (100%) · $0 remaining · first sale May 29, 2020 |
| Filing timing | Date of first sale: May 29, 2020 · Form D filed: Jun 10, 2020 (12 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,339 days (6.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 24 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity; Security to be acquired upon exercise |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | MTS Partners — no CRD number reported Solicits in: CA, CO, CT, NY |
| Money to insiders | Sales commissions: $4,800,000 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Michael Celano, Chief Financial Officer (Jun 6, 2020) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $80,000,000. Typical range: $2,000,000–$19,999,994. Investors: 24. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Dec 5, 2012 SEC file no. 021-187910 · accession 0001374690-12-000003 |
|---|---|
| Raise progress | $21,761,570 sold of Indefinite offered · Indefinite remaining · first sale Nov 30, 2012 |
| Filing timing | Date of first sale: Nov 30, 2012 · Form D filed: Dec 5, 2012 (5 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 5,076 days (13.9 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 4 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Other Health Care |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Matthias Jaffe, CFO (Dec 5, 2012) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$54,310. Offering size: Indefinite. Typical range: $829,831–$9,999,998. Investors: 4. Typical range: 2–15. "Similar" = Other Health Care, Rule 506(b). Based on 4,189 Form D filings 2021–2026 in the same industry and exemption (Other Health Care, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 1,330, offering size 3,970, investors 3,669. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Aug 28, 2012 SEC file no. 021-183316 · accession 0001374690-12-000001 |
|---|---|
| Raise progress | $3,000,000 sold of Indefinite offered · Indefinite remaining · first sale Aug 13, 2012 |
| Filing timing | Date of first sale: Aug 13, 2012 · Form D filed: Aug 28, 2012 (15 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 5,185 days (14.2 years) |
| Annual amendments | Issuer reported the offering may last more than one year. No amendment for this offering in our index (filings 2008 → Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 2 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Debt |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Other Health Care |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Matthias Jaffe, CFO, Treasurer and VP of Business Development (Aug 27, 2012) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$54,310. Offering size: Indefinite. Typical range: $829,831–$9,999,998. Investors: 2. Typical range: 2–15. "Similar" = Other Health Care, Rule 506(b). Based on 4,189 Form D filings 2021–2026 in the same industry and exemption (Other Health Care, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 1,330, offering size 3,970, investors 3,669. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Jul 12, 2011 SEC file no. 021-162666 · accession 0001374690-11-000001 |
|---|---|
| Raise progress | $6,085,933 sold of Indefinite offered · Indefinite remaining · first sale Jun 30, 2011 |
| Filing timing | Date of first sale: Jun 30, 2011 · Form D filed: Jul 12, 2011 (12 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 5,595 days (15.3 years) |
| Annual amendments | Issuer reported the offering may last more than one year. No amendment for this offering in our index (filings 2008 → Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 6 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Other Health Care |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.) |
| Signed by | Matthias Jaffe, CFO, Treasurer & VP of Business Development (Jul 12, 2011) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$54,310. Offering size: Indefinite. Typical range: $829,831–$9,999,998. Investors: 6. Typical range: 2–15. "Similar" = Other Health Care, Rule 506(b). Based on 4,189 Form D filings 2021–2026 in the same industry and exemption (Other Health Care, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 1,330, offering size 3,970, investors 3,669. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D/A (amendment) filed Mar 2, 2010 · amends 0001374690-10-000003 ↗ SEC file no. 021-94401 · accession 0001374690-10-000004 · filing 2 of 2 in this offering |
|---|---|
| Raise progress | $8,100,000 sold of $10,125,000 offered (80%) · $2,025,000 remaining · first sale Feb 17, 2010 |
| Filing timing | Date of first sale: Feb 17, 2010 · Original Form D filed: Mar 1, 2010 (12 days after first sale) · This amendment (Form D/A) filed: Mar 2, 2010 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
| Time since first sale | 6,093 days (16.7 years) |
| Annual amendments | Issuer reported the offering may last more than one year. This filing is an amendment dated Mar 2, 2010. Most recent amendment for this offering in our index: this filing, Mar 2, 2010. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 3 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Other Health Care |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Matthias Jaffe, CFO, Treasurer & VP of Business Development (Mar 2, 2010) |
| Changes vs previous filing |
Compared with the D filed Mar 1, 2010 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$54,310. Offering size: $10,125,000. Typical range: $829,831–$9,999,998. Investors: 3. Typical range: 2–15. "Similar" = Other Health Care, Rule 506(b). Based on 4,189 Form D filings 2021–2026 in the same industry and exemption (Other Health Care, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 1,330, offering size 3,970, investors 3,669. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Mar 1, 2010 SEC file no. 021-94401 · accession 0001374690-10-000003 · filing 1 of 2 in this offering |
|---|---|
| Raise progress | $8,100,000 sold of $10,125,000 offered (80%) · $2,025,000 remaining · first sale Feb 17, 2010 |
| Filing timing | Date of first sale: Feb 17, 2010 · Form D filed: Mar 1, 2010 (12 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 6,093 days (16.7 years) |
| Annual amendments | Issuer reported the offering may last more than one year. Most recent amendment for this offering in our index: Mar 2, 2010 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 3 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Other Health Care |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Matthias Jaffe, CFO, Treasurer & VP of Business Development (Mar 1, 2010) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$54,310. Offering size: $10,125,000. Typical range: $829,831–$9,999,998. Investors: 3. Typical range: 2–15. "Similar" = Other Health Care, Rule 506(b). Based on 4,189 Form D filings 2021–2026 in the same industry and exemption (Other Health Care, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 1,330, offering size 3,970, investors 3,669. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Amendment filed | File no. | Compared with | What changed (both values as filed) |
|---|---|---|---|
| Mar 2, 2010 EDGAR ↗ | 021-94401 | Mar 1, 2010 D | related persons added (Mar 2, 2010): Avi S. Goldberg · related persons no longer listed (Mar 2, 2010): Ari S. Goldberg |
Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.
All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Jun 10, 2020. Industry as reported, by offering: Previous offerings: Other Health Care (2010–2012). Latest offering: Biotechnology (2020; most recent Jun 10, 2020).
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|---|---|---|---|
| Carole Ben-Maimon also filed as Carole Ben Maimon; MD | Executive Officer, Director Issuer's note: President and CEO | PA | Jun 10, 2020 on 2 of 7 filings listed on the latest filing | 1 other issuer |
| Frank E. Thomas | Director | PA | Jun 10, 2020 on 2 of 7 filings listed on the latest filing | 1 other issuer |
| Jonathan Leff | Director | PA | Jun 10, 2020 on 2 of 7 filings listed on the latest filing | 1 other issuer |
| Joseph Truitt | Director | PA | Jun 10, 2020 on 2 of 7 filings listed on the latest filing | 1 other issuer |
| Michael Celano | Executive Officer Issuer's note: Chief Financial Officer | PA | Jun 10, 2020 on 2 of 7 filings listed on the latest filing | — |
| Peter Barrett | Director | PA | Aug 28, 2012 → Jun 10, 2020 on 1 of 7 filings listed on the latest filing | 7 other issuers |
| Thomas Hamilton | Director | PA | Jun 10, 2020 on 2 of 7 filings listed on the latest filing | — |
| Thomas O. Daniel | Director | PA | Jun 10, 2020 on 2 of 7 filings listed on the latest filing | — |
| Avi S. Goldberg also filed as Avi Goldberg | Director | MA | Mar 2, 2010 → Dec 5, 2012 on 4 of 7 filings not listed on the latest filing (Jun 10, 2020) | — |
| Bruce S. Booth | Director | MA | Mar 1, 2010 → Dec 5, 2012 on 4 of 7 filings not listed on the latest filing (Jun 10, 2020) | — |
| Dennis D. Kim | Executive Officer | MA | Dec 5, 2012 on 1 of 7 filings not listed on the latest filing (Jun 10, 2020) | — |
| Frances Heller also filed as Frances S. Heller | Director | MA | Aug 28, 2012 → Dec 5, 2012 on 2 of 7 filings not listed on the latest filing (Jun 10, 2020) | 1 other issuer |
| Kevin S. Starr | Director | MA | Mar 1, 2010 → Dec 5, 2012 on 4 of 7 filings not listed on the latest filing (Jun 10, 2020) | — |
| Lou S. Tartaglia | Director | MA | Dec 5, 2012 on 1 of 7 filings not listed on the latest filing (Jun 10, 2020) | — |
| Matthias Jaffe | Executive Officer Issuer's note: CFO, Treasurer & VP of Business Development | MA | Mar 1, 2010 → Dec 5, 2012 on 5 of 7 filings not listed on the latest filing (Jun 10, 2020) | — |
| Mitchell S. Bloom also filed as Mitchell Bloom | Executive Officer Issuer's note: Secretary | MA | Mar 1, 2010 → Dec 5, 2012 on 5 of 7 filings not listed on the latest filing (Jun 10, 2020) | 11 other issuers |
| Peter S. Barrett | Director | MA | Mar 1, 2010 → Dec 5, 2012 on 4 of 7 filings not listed on the latest filing (Jun 10, 2020) | — |
| Thomas Hughes | Executive Officer, Director Issuer's note: CEO & President | MA | Mar 1, 2010 → Dec 5, 2012 on 5 of 7 filings not listed on the latest filing (Jun 10, 2020) | 1 other issuer |
| Bruce Booth | Director | MA | Aug 28, 2012 on 1 of 7 filings not listed on the latest filing (Jun 10, 2020) | 17 other issuers |
| Kevin Starr | Director | MA | Aug 28, 2012 on 1 of 7 filings not listed on the latest filing (Jun 10, 2020) | 4 other issuers |
| Lou Tartaglia | Director | MA | Aug 28, 2012 on 1 of 7 filings not listed on the latest filing (Jun 10, 2020) | 3 other issuers |
| Louis S. Tartaglia | Director | MA | Mar 1, 2010 → Jul 12, 2011 on 3 of 7 filings not listed on the latest filing (Jun 10, 2020) | — |
| Dr. Liam S. Ratcliffe | Director | MA | Mar 1, 2010 → Mar 2, 2010 on 2 of 7 filings not listed on the latest filing (Jun 10, 2020) | — |
| Ari S. Goldberg | Director | MA | Mar 1, 2010 on 1 of 7 filings not listed on the latest filing (Jun 10, 2020) | — |
Executive officers, directors and promoters as self-reported by the issuer; spelling variants of one person are merged. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Other issuers listing the same people (showing 40 of 48):
Shared address: this business address appears on filings for 4 other issuers. Stated as a count only (suite numbers ignored) — many addresses are shared office buildings or registered agents. As of Oct 23, 2026, 5:45 PM ET.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Not yet searched. Sources to be searched: SEC Investment Adviser Information Reports — Form ADV data for SEC-registered advisers and exempt reporting advisers (file dated 2026-10-02); SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet collected.
Sources to be searched: sponsor website, Internet Archive, press index (GDELT), Form ADV. A sponsor's website is known only from an approved profile claim or the issuer's own Form ADV; we never look it up elsewhere and never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for PA yet).
Export this report as PDF (all source links + data timestamp; members · included free during the launch period)
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.
The complete public-record profile for Larimar Therapeutics, Inc., plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a verified contact for corrections. Claiming never changes the public-record section.